Hongwei Ma: Department of Neurosurgery, Chinese PLA General Hospital, No. 28 Fuxing Road, Beijing 100853, PR China; School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, PR China.
Zhiyong Gao: Department of anesthesiology, Aviation Industry of China 363 Hospital, Chengdu 610041, PR China.
Panfeng Yu: Department of Orthopaedics, Chinese Air Force General Hospital, No. 30 Fucheng Road, Beijing 100142, PR China.
Shun Shen: Department of Neurosurgery, Chinese Air Force General Hospital, No. 30 Fucheng Road, Beijing 100142, PR China. Electronic address: shjwkk@sina.com.
Yongmei Liu: Department of Thoracic Oncology,Cancer center, West China Hospital, Sichuan University, Chengdu 610041, PR China. Electronic address: lymi75@163.com.
Bainan Xu: Department of Neurosurgery, Chinese PLA General Hospital, No. 28 Fuxing Road, Beijing 100853, PR China.
Glioma is a huge threat for human being because it was hard to be completely removed owing to both the infiltrating growth of glioma cells and integrity of blood brain barrier. Thus effectively imaging the glioma cells may pave a way for surgical removing of glioma. In this study, a fluorescent probe, Cy3, was anchored onto the terminal of AS1411, a glioma cell targeting aptamer, and then TGN, a BBB targeting peptide, was conjugated with Cy3-AS1411 through a PEG linker. The production, named AsT, was characterized by gel electrophoresis, (1)H NMR and FTIR. In vitro cellular uptake and glioma spheroid uptake demonstrated the AsT could not only be uptaken by both glioma and endothelial cells, but also penetrate through endothelial cell monolayer and uptake by glioma spheroids. In vivo, AsT could effectively target to glioma with high intensity. In conclusion, AsT could be used as an effective glioma imaging probe.
